Q-Curviva logo

Powered by QuanticSphere™

Curcumin that reaches clinically relevant plasma levels

Nanostructured QuanticSphere™ delivery stabilizes curcuminoids, promotes membrane interaction, and sustains exposure at nutritionally feasible doses.

Maintains ~40-fold higher concentration at 8 hr vs raw curcumin.

Value Proposition

The three pillars of Q-Curviva™

Protection

  • Phospholipids shield from acid and enzymatic degradation.
  • Enhanced chemical stability under stress conditions.

Programmability

  • Sustained release to smooth peaks and troughs.
  • Designed for once-daily use in many contexts.

Precision

  • Cationic surface promotes membrane interaction and uptake.
  • Clinically meaningful exposure at lower doses.

Pharmacokinetics

Time–concentration profile of
Q-Curviva™

Faster onset, sustained plasma exposure, enhanced absorption, superior clinical potential.

  • Faster onset of action: Q-Curviva™ reaches meaningful plasma levels more quickly.
  • Sustained effect: Concentrations remain elevated over time, extending curcumin’s activity window.
  • QuanticSphere™ advantage: Nanostructured delivery enhances both absorption and molecular stability.
  • Limitations of unformulated curcumin: Poor bioavailability leads to persistently low plasma levels and limited clinical impact.
Curcumin plasma concentration over 480 minutes (Q-Curviva vs Unformulated)

Mechanisms

How Q-Curviva™ works

Anti-inflammatory▾

Down-regulates NF-κB/COX-2 and cytokines (TNF-α, IL-1β, IL-6).

Antioxidant▾

Direct ROS scavenging and Nrf2 activation elevate endogenous defenses.

Cell signaling▾

Modulates PI3K/AKT and MAPK pathways; supportive epigenetic effects.

PQNS advantage▾

Vesicles protect curcuminoids, adhere/fuse with enterocytes, and enable controlled release → higher plasma exposure with excellent GI tolerance.

Dosing

Evidence-aligned options

Maintenance / Prevention

Once daily
Q-Curviva™ 100 mg

Supports long-term antioxidant and anti-inflammatory tone with minimal GI load.

Optional co-actives per clinician judgment.

Therapeutic / Anti-inflammatory

Once daily
Q-Curviva™ 150 mg

For symptomatic OA, metabolic inflammation, or neuroinflammatory contexts.

Reassess at 8–12 weeks under clinician guidance.

Formulated with GRAS-status phospholipids. Evaluate potential interactions when adding absorption enhancers or co-actives.

Comparison

Positioning vs standard curcumin

CategoryStandard CurcuminQ-Curviva™ (QuanticSphere™)
Peak Plasma (Cmax)≈ 67 ng/mL @ 1000 mg≈ 308 ng/mL @ 350 mg
Total Exposure (AUC₀–last)≈ 698 ng·h/mL≈ 2 582 ng·h/mL
Typical Daily Dose1000–2000 mg100–150 mg
GI TolerabilityHigh-dose GI upset more commonPhospholipid matrix, gut-friendly profile

Next steps

Bring Q-Curviva™ to your clinic

Request the full white paper, PK appendix, COAs, and sample protocols.

Downloads

  • Q-Curviva™ White Paper (PDF)
  • One-page PK summary
  • Clinician dosing guide

Based on September 2025 dossier and internal PK study.

Ready to Experience Q-Curviva™?

Q-Curviva retail box

Clinically engineered multi-pathway therapeutic system for osteoarthritis.

Request Pricing
For clinicians and healthcare professionals. Information is educational and not a substitute for medical advice. Availability, labeling, and claims may vary by market.